Immucell (ICCC) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Immucell Corporation  (NASDAQ: ICCC)


Immucell's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ICCC Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change 49.91 %
Seq. Revenue Change 11.88 %
Revenue In Millions $8.04
Gross Profit Margin 0 %
Gross Profit Margin Total Ranking # 2135
Gross Profit In Millions $0.00
Y / Y Gross Profit Change -
Seq. Gross Profit Change -


Commenting Third Quarter 2026 Gross Profit Margin
Immucell Corporation recorded Gross Loss compared to Gross Profit achieved in the preceding quarter.


Observing third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Gross Profit Margin. While overall Gross Profit Margin ranking remained unchanged compared to the previous quarter at no. .
Learn about Gross Margin
ICCC's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 449
Overall # 2135

Gross Profit Margin Statistics
High Average Low
65.2 % 45.3 % 3.21 %
(Sep 30 2015)   (Dec 31 2018)


ICCC Gross Income Trends • More of ICCC's Profitabilty Ratios • ICCC Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ICCC's Cumulative Gross Profit Margin
In Vitro & In Vivo Diagnostic Substances Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ICCC's Gross Profit Margin Profitability versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ICCC's Competitors
Gross Profit Margin Profit Margin for Immucell's Suppliers
Gross Profit Margin Profit Margin for ICCC's Customers

You may also want to know
ICCC's Annual Growth Rates ICCC's Profitability Ratios ICCC's Asset Turnover Ratio ICCC's Dividend Growth
ICCC's Roe ICCC's Valuation Ratios ICCC's Financial Strength Ratios ICCC's Gross Profit Growth
ICCC's Roa ICCC's Inventory Turnover Ratio ICCC's Growth Rates ICCC's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.